|
|
|
|
Astex presents updates on AT7519 and AT9283 at the American Society of Hematology (ASH) Conference
Cambridge, England, 1st December, 2008 - Astex Therapeutics Limited, the leading fragment based drug discovery company, today announced that it is to present key findings on two of its clinical stage compounds, AT7519 and AT9283, at the 50th...
|
|
|
Correlation Between HBV cccDNA And HBsAg Levels And Their Reduction By Peginterferon Alfa-2a-Based Therapy In
Conference Reports for NATAP 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) Oct 31-Nov 1 2008 San Francisco, CA Back  Reported by Jules Levin 59th Annual Meeting of the American Association...
|
|
|
Liver disease tackled with dedicated unit at Imperial College London
A new 1m clinical research facility dedicated to tackling liver disease, the fifth most common cause of death in the UK, opens today at Imperial College London.Liver disease death rates are rising in the UK, in contrast to other common...
|
|
|
Conjunctival hemorrhagic events associated with imatinib mesylate
Radaelli F et al.- Imatinib mesylate (IM) is used in the targeted therapy of chronic myelogenous leukemia and gastrointestinal stromal tumors. Conjunctival hemorrhagic events associated with imatinib mesylate.
|
|
|
Kinetics Of HBsAg Decline in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Peginterferon alfa-
HBsAg clearance/seroconversion (loss of HBsAg and appearance of anti-HBs) can be considered the closest we can achieve to clinical cure of chronic hepatitis B infection Interferon-based therapy can induce HBsAg clearance...
|
|
|
Quantitative Assessment Of Serum HBsAg Levels Using The Elecsys HBsAg II Screening Assay: Results Of A Feasibi
Conference Reports for NATAP 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) Oct 31-Nov 1 2008 San Francisco, CA Back  Reported by Jules Levin 59th Annual Meeting of the American Association...
|
|
|
In Patients With HBeAg-Negative Chronic Hepatitis B, HBsAg Serum Levels Early During Treatment With Peginterfe
Conference Reports for NATAP 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) Oct 31-Nov 1 2008 San Francisco, CA Back  Reported by Jules Levin 59th Annual Meeting of the American Association...
|
|
|
Rationale and Strategies for Early Detection and Management of Diabetic Kidney Disease
Radbill B et al.- Diabetic kidney disease (DKD) occurs in 20% to 40% of patients with diabetes mellitus and is the leading cause of chronic kidney disease and end-stage renal disease in the United States. Many patients with...
|
|
|
Scientists track genetic changes in leukemia
WASHINGTON (Reuters) - Distinctive genetic changes occur in the cancer cells that trigger relapse in patients with the most common type of childhood cancer, according to a study that may offer new hope for beating the disease.
|
|
|
Miscreant myeloproliferative disorder stem cells FREE
Myeloproliferative disorders (MPDs), typified by robust marrow and extramedullary hematopoiesis, have a propensity to progress to acute leukemia.Although the hematopoietic stem cell (HSC) origin of MPDs was suggested over 30...
|
|
|
Asuragen, Inc. Launches a Multiplex qRT-PCR Assay for the Detection of BCR/ABL1 Fusion Transcripts
- Asuragen, Inc.announced today the launch of its BCR/ABL1 Quant (RUO)* kit, a research tool utilizing multiplex real-time quantitative RT-PCR to provide simultaneous detection and quantification of BCR/ABL1 fusion transcripts (b2a2, b3a2...
|
|
|
Asuragen, Inc. Launches a Multiplex qRT-PCR Assay for the Detection of BCR/ABL1 Fusion Transcripts
Asuragen, Inc.announced today the launch of its BCR/ABL1 Quant (RUO)* kit, a research tool utilizing multiplex real-time quantitative RT-PCR to provide simultaneous detection and quantification of BCR/ABL1 fusion transcripts (b2a2, b3a2,...
|
|
|
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics, today announced new data from its studies of voreloxin in acute myeloid ...
|
|
|
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
t 11:00 am ET to Discuss Phase 2 Study Results in AML -- SOUTH SAN FRANCISCO, Calif., Dec.1 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of new...
|
|
|
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
t 11:00 am ET to Discuss Phase 2 Study Results in AML -- SOUTH SAN FRANCISCO, Calif., Dec.1 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of new...
|
|
|
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
t 11:00 am ET to Discuss Phase 2 Study Results in AML -- SOUTH SAN FRANCISCO, Calif., Dec.1 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of new...
|
|
|
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
t 11:00 am ET to Discuss Phase 2 Study Results in AML -- SOUTH SAN FRANCISCO, Calif., Dec.1 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of new...
|
|
|
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
t 11:00 am ET to Discuss Phase 2 Study Results in AML -- SOUTH SAN FRANCISCO, Calif., Dec.1 /PRwire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: - ), a biopharmaceutical company focused on the development and commercialization...
|
|
|
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of the NS3/4A
San Francisco, CA B.Bradford1 , C. Rubino2, S. Porter1, A. Forrest2, L. Blatt1, A. Patat3 1InterMune, Inc., Brisbane, CA ; 2ICPD/Ordway Research Institute, Inc., Albany, NY, SUNY School of Pharmacy, Buffalo, NY; 3 Biotrial...
|
|
|
Pharmacokinetic-Pharmacodynamic (PK-PD) Relationships for ITMN-191 in a Phase 1 Multiple Ascending Dose (MAD)
Rubino1 , B.Bradford2, S. Porter2, A. Forrest1, L. Blatt2, A. Patat3 1ICPD/Ordway Research Institute, Inc., Albany, NY InterMune, Inc., Brisbane, CA ; 2InterMune, Inc., Brisbane, CA ; 3Biotrial, Rennes, France BACKGROUND ...
|
|
|
HIV+ and looking to conceive
a unique group will occupy the waiting room at Mount Sinai Hospital's fertility clinic in Toronto.These people, like the couples who are welcome here year-round, dream of having children. Yet, when the two weeks are up, equipment...
|
|
|
15 million people suffering from Hepatitis B & C F.P Report
KARACHI: Fifteen million people are suffering from hepatitis B & C in the country, said Dr Zaigham Abbas, Consultant Gastroenterologist.He was speaking at a press conference on the first day of second annual congress of Pakistan...
|
|
|
Researchers Discover Genetic Changes In Child Leukemia
Scientists may have gained new insights into the genetic changes in cancer cells that trigger relapse in patients with acute lymphoblastic leukemia.ALL, a cancer of the blood and bone marrow is the most common type of...
|
|
|
Scientists track genetic changes in leukemia
WASHINGTON (Reuters) - Distinctive genetic changes occur in the cancer cells that trigger relapse in patients with the most common type of childhood cancer, according to a study that may offer new hope for beating the disease.
|
|
|
Researchers track genetic changes in leukemia
TWN, By Will Dunham, Reuters WASHINGTON -- Distinctive genetic changes occur in the cancer cells that trigger relapse in patients with the most common type of childhood cancer, according to a study that may offer new hope for beating...
|
